Discover

PLX
Protalix BioTherapeutics, Inc.
2.35
5 x 2.34
4 x 2.35
bid
ask
-
0.01
0.42%
11:59 AM
timesize
Ytd30.56%
1y48.73%
2.31
day range
2.37
1.41
52 week range
3.19
Open2.34Prev Close2.36Low2.31High2.37Mkt Cap190.15M
Vol85.04KAvg Vol724.14KEPS0.18P/E12.97Forward P/E2.79
BetaN/AShort Ratio22.71Inst. Own5.20%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1350-d Avg2.15200-d Avg2.221yr Est14.00

PLX News

12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
seekingalpha.com
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

Earnings Scheduled For May 13, 2026
benzinga.com
Earnings Scheduled For May 13, 2026

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
prnewswire.com
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution con

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
prnewswire.com
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswir

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance
seekingalpha.com
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78

Americans are richer in shares, Europeans in bricks – and that matters now
proactiveinvestors.com
Americans are richer in shares, Europeans in bricks – and that matters now

American and European households may be growing wealthier at a similar pace, but the composition of

Tesla targets December 2026 for next-generation AI6 chip tape-out
proactiveinvestors.com
Tesla targets December 2026 for next-generation AI6 chip tape-out

Tesla Inc (NASDAQ:TSLA) CEO Elon Musk on Thursday shared an update on the company’s semiconductor pl

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
seekingalpha.com
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
proactiveinvestors.com
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined

Earnings Scheduled For March 18, 2026
benzinga.com
Earnings Scheduled For March 18, 2026

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
prnewswire.com
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) appr

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
proactiveinvestors.com
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined

Pennon shares rise despite profit warning as storm costs and sewage penalties bite
proactiveinvestors.com
Pennon shares rise despite profit warning as storm costs and sewage penalties bite

Shares in Pennon Group PLC (LSE:PNN, OTC:PEGRY) rose 3.4% to 553.5p on Tueaday morning despite the o

Physiomics shares fall 27% after discounted share placing
proactiveinvestors.com
Physiomics shares fall 27% after discounted share placing

AIM modelling company raises £450,000 at a steep discount, betting that investment in growth will ju

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
proactiveinvestors.com
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has appro

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
proactiveinvestors.com
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has appro

Ticketmaster owner Live Nation reaches antitrust settlement with US Justice Department
proactiveinvestors.com
Ticketmaster owner Live Nation reaches antitrust settlement with US Justice Department

The US Justice Department has reportedly reached a settlement with Ticketmaster and its parent compa

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
globenewswire.com
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Ad

This press release is intended for US audiences for transparency relative to global news for the Fab

Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT)
defenseworld.net
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT)

Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and JATT Acquisition (NYSE: JATT - Get Free R

Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
globenewswire.com
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Compan

Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in th

A March Decision That Could Change Protalix BioTherapeutics Outlook
seekingalpha.com
A March Decision That Could Change Protalix BioTherapeutics Outlook

Protalix Bio Therapeutics (PLX) received a positive CHMP opinion for Elfabrio's every-four-weeks dos

Protalix wins EU panel backing for expanded dosing of Fabry disease drug
proactiveinvestors.com
Protalix wins EU panel backing for expanded dosing of Fabry disease drug

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) said on Friday that the European Medicines Agenc

Earnings Scheduled For November 13, 2025
benzinga.com
Earnings Scheduled For November 13, 2025

benzinga.com
Earnings Scheduled For August 14, 2025

benzinga.com
Earnings Scheduled For March 17, 2025

benzinga.com
Earnings Scheduled For November 6, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

benzinga.com
Earnings Scheduled For August 15, 2022

  Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings f

benzinga.com
Earnings Scheduled For October 29, 2020

  Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings